BioNTech's €16.8 Billion War Chest Can't Mask the Red Ink as ASCO Showdown Looms
18.05.2026 - 22:02:50 | boerse-global.de
The numbers tell a story of two companies in one. BioNTech's balance sheet boasts a fortress-like €16.8 billion in cash and securities, yet its income statement bleeds more than half a billion euros in a single quarter. The German biotech is plowing through its coronavirus-era riches at breakneck speed, funding an expensive metamorphosis from vaccine manufacturer into oncology powerhouse.
First-quarter revenue slumped to €118.1 million from €183 million a year earlier, while the net loss ballooned to €531.9 million. The culprit: a surge in research and development spending to €557 million as the company pours resources into its pipeline. Management is betting the entire future on the cancer drug candidate Pumitamig, and the next major test arrives within days.
A Board Overhaul Signals Shift in Priority
Shareholders have given the green light to a governance shake-up designed to support the oncology pivot. The supervisory board expands from six to eight members, with the addition of Iris Löw-Friedrich and Susanne Schaffert, two seasoned pharmaceutical executives whose expertise spans clinical development and cancer-drug commercialization. Helmut Jeggle retains the chairmanship, and the mandates of two other board members were extended.
The timing is deliberate. BioNTech now runs more than 20 late-stage clinical trials, and the board refresh brings in the kind of know-how needed to navigate the regulatory and marketing complexities of bringing cancer therapies to market.
Should investors sell immediately? Or is it worth buying BioNTech?
Costs are also being trimmed on the vaccine side. From the end of 2026, partner Pfizer will assume full commercial production of the COVID-19 shots, allowing BioNTech to wind down multiyear supply agreements and focus its resources on oncology. The company maintains its full-year revenue guidance of €2 billion to €2.3 billion.
Pumitamig Faces Its First Real Test
All eyes are on the annual meeting of the American Society of Clinical Oncology (ASCO), where BioNTech will present phase 2 data from the ROSETTA-Lung-02 study. The trial pits Pumitamig combined with chemotherapy against the established standard, pembrolizumab, in first-line treatment of non-small-cell lung cancer. The head-to-head design means results could either validate the entire oncology pipeline or send it back to the drawing board.
The data release is scheduled between May 29 and June 2. Positive readouts would provide the first solid proof that billion-euro investments in oncology are beginning to pay off. A disappointment, however, would test the stock's recent floor.
Stock Under Pressure as Analysts Trim Targets
BioNTech shares currently trade at around €75.60, having lost roughly 13% over the past month. The stock sits just above its 52-week low of €72.50 and 13% below its 200-day moving average of €87, underscoring a persistent downtrend.
BioNTech at a turning point? This analysis reveals what investors need to know now.
Analysts are adjusting their expectations. Berenberg cut its price target to $140, while Canaccord Genuity lowered its forecast to $158 but maintains a buy recommendation. The market's patience is wearing thin as the company burns cash faster than it generates revenue, but the timeline for a pipeline payoff is fast approaching.
If Pumitamig delivers strong results at ASCO, the narrative could flip overnight. If not, the €16.8 billion cushion may be the only thing keeping the stock from testing new lows.
Ad
BioNTech Stock: New Analysis - 18 May
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
So schätzen die Börsenprofis BioNTechs Aktien ein!
FĂĽr. Immer. Kostenlos.
